Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial

A class of drugs commonly used for diabetes and obesity is showing potential to treat Parkinson’s disease. In a small mid-stage trial, an older diabetes treatment called lixisenatide helped slow down the progression of motor disability in patients with early-stage Parkinson’s disease. The drug is similar to Novo Nordisk’s Ozempic and Wegovy. Motor disability symptoms include tremors, stiffness, and slow movement. However, larger and longer studies are needed to determine the drug’s efficacy and safety. The results mark progress in finding treatments for Parkinson’s disease, which affects hundreds of thousands of Americans. The study was funded by the French Ministry of Health and Prevention and a UK charity called Cure Parkinson’s. Attribution